The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...

AN2 Therapeutics , Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on developing treatments for infectious diseases, ...

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (SLN – Research Report) and keeping the price ...

Johnson & Johnson is contributing $1 million to support the development of curricula and modernization of training and lab ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

February 06, 2025--(BUSINESS WIRE)--Cadrenal Therapeutics ... therapy as well as other business development opportunities to build the Company’s pipeline. Dr. Ferguson replaces Douglas W.

Pham, Chief Executive Officer, Cadrenal Therapeutics ... therapy as well as other business development opportunities to build the Company’s pipeline, as well as advancing other indications ...

Roche will continue a careful approach to high-priced deals, putting science at the center of its business development ...